Insider Selling: Sera Prognostics (NASDAQ:SERA) Insider Sells $16,288.72 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Tiffany Eul Davis Inglis sold 8,024 shares of Sera Prognostics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $2.03, for a total value of $16,288.72. Following the completion of the transaction, the insider owned 83,565 shares of the company’s stock, valued at approximately $169,636.95. The trade was a 8.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tiffany Eul Davis Inglis also recently made the following trade(s):

• On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total value of $972.00.

Sera Prognostics Trading Down 1.9%

Shares of Sera Prognostics stock opened at $2.03 on Friday. The business’s 50 day simple moving average is $2.05 and its 200-day simple moving average is $2.02. The stock has a market capitalization of $80.08 million, a price-to-earnings ratio of -3.03 and a beta of 1.06. Sera Prognostics, Inc. has a twelve month low of $1.56 and a twelve month high of $3.95.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.07 million. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Several large investors have recently made changes to their positions in SERA. Sanders Morris Harris LLC acquired a new position in shares of Sera Prognostics during the third quarter worth approximately $642,000. AWM Investment Company Inc. bought a new position in Sera Prognostics in the 2nd quarter worth approximately $377,000. Segall Bryant & Hamill LLC bought a new position in Sera Prognostics in the 1st quarter worth approximately $193,000. Finally, Arkadios Wealth Advisors acquired a new stake in Sera Prognostics in the 1st quarter valued at approximately $25,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.